Evidence map›Paper›PMID 26608132›Full record

ArticleBMC immunology2015

Impact of microRNA-130a on the neutrophil proteome.

Corinna Cavan Pedersen, Jan Christian Refsgaard, Ole Østergaard, Lars Juhl Jensen, Niels Henrik Helweg Heegaard, Niels Borregaard, Jack Bernard Cowland

Abstract read
In one paragraph

Article in BMC immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Corinna Cavan PedersenThe Granulocyte Research Laboratory, Department of Hematology, National University Hospital, University of Copenhagen, 9322, Blegdamsvej 9, DK-2100, Copenhagen Ø, Denmark. corinna.cavan.pedersen@regionh.dk.
Jan Christian RefsgaardDisease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark. jan.refsgaard@cpr.ku.dk.
Ole ØstergaardDepartment of Autoimmunology & Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300, Copenhagen S, Denmark. ooe@ssi.dk.
Lars Juhl JensenDisease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark. lars.juhl.jensen@cpr.ku.dk.
Niels Henrik Helweg HeegaardDepartment of Autoimmunology & Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300, Copenhagen S, Denmark. nhe@ssi.dk.
Niels BorregaardThe Granulocyte Research Laboratory, Department of Hematology, National University Hospital, University of Copenhagen, 9322, Blegdamsvej 9, DK-2100, Copenhagen Ø, Denmark. niels.borregaard@regionh.dk.
Jack Bernard CowlandThe Granulocyte Research Laboratory, Department of Hematology, National University Hospital, University of Copenhagen, 9322, Blegdamsvej 9, DK-2100, Copenhagen Ø, Denmark. jack.cowland@regionh.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) are important for the development and function of neutrophils. miR-130a is highly expressed during early neutrophil development and regulates target proteins important for this process. miRNA targets are often identified by validating putative targets found by in silico prediction algorithms one at a time. However, one miRNA can have many different targets, which may vary depending on the context. Here, we investigated the effect of miR-130a on the proteome of a murine and a human myeloid cell line.

resultsUsing pulsed stable isotope labelling of amino acids in cell culture and mass spectrometry for protein identification and quantitation, we found 44 and 34 proteins that were significantly regulated following inhibition of miR-130a in a miR-130a-overexpressing 32Dcl3 clone and Kasumi-1 cells, respectively. The level of miR-130a inhibition correlated with the impact on protein levels. We used RAIN, a novel database for miRNA-protein and protein-protein interactions, to identify putative miR-130a targets. In the 32Dcl3 clone, putative targets were more up-regulated than the remaining quantified proteins following miR-130a inhibition, and three significantly derepressed proteins (NFYC, ISOC1, and CAT) are putative miR-130a targets with good RAIN scores. We also created a network including inferred, putative neutrophil miR-130a targets and identified the transcription factors Myb and CBF-β as putative miR-130a targets, which may regulate the primary granule proteins MPO and PRTN3 and other proteins differentially expressed following miR-130a inhibition in the 32Dcl3 clone.

conclusionWe have experimentally identified miR-130a-regulated proteins within the neutrophil proteome. Linking these to putative miR-130a targets, we provide an association network of potential direct and indirect miR-130a targets that expands our knowledge on the role of miR-130a in neutrophil development and is a valuable platform for further experimental studies.

Indexed as

ProteomeAnimalsCell LineGene Expression RegulationGene Regulatory NetworksMiceMicroRNAsMyeloid CellsNeutrophilsProteomicsMicroRNAsMIRN130 microRNA, mouseProteome

Identifiers

PMID26608132
PMCPMC4659159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.